ネブラスカ州における卵巣がんの臨床試験
ネブラスカ州内の拠点で、卵巣がんに関する15件の研究が参加者を募集しています。
ネブラスカ州内の都市
公式研究テキスト（英語）
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- Nebraska Cancer Specialists, Omaha
- XCancer, Omaha
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07189871A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
- University Of Nebraska Medical Center /ID# 281020, Omaha
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07278336First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
- University of Nebraska Medical Center, Omaha
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/29更新 · NCT06799065A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Nebraska Cancer Specialists, Omaha
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07109726A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Nebraska Methodist Hospital ( Site 0004), Omaha
- University Of Nebraska Medical Center ( Site 0035), Omaha
被験者募集中第3相
18歳以上 · 女性 · 2026/09/17更新 · NCT07318558A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Nebraska Methodist Hospital, Omaha
被験者募集中第2相
18歳〜99歳 · 女性 · 2026/09/15更新 · NCT07023627A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Nebraska Methodist Hospital ( Site 0053), Omaha
被験者募集中第3相
18歳以上 · 女性 · 2026/09/03更新 · NCT06824467Study of NTB-928 in R/R OC
- University of Nebraska Medical Center, Omaha
被験者募集中第1相
18歳以上 · 女性 · 2026/08/20更新 · NCT07690189A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Fred and Pamela Buffett Cancer Center - Kearney, Kearney
- Nebraska Cancer Specialists/Oncology Hematology West PC - MECC, Omaha
- Nebraska Methodist Hospital, Omaha
- 他2件
被験者募集中
35歳〜50歳 · 女性 · 2026/08/07更新 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Nebraska Medicine-Bellevue, Bellevue
- CHI Health Saint Francis, Grand Island
- Fred and Pamela Buffett Cancer Center - Kearney, Kearney
- 他8件
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/07更新 · NCT06580314A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Nebraska Cancer Specialists - Midwest Cancer Center - Legacy, Omaha
被験者募集中第2相
8歳以上 · 全性別 · 2026/07/27更新 · NCT05503797Lead-212 PSV359 Therapy for Patients With Solid Tumors
- Nebraska Cancer Specialists, Omaha
被験者募集中第1/2相
18歳〜90歳 · 全性別 · 2026/07/06更新 · NCT06710756Integrated Cancer Repository for Cancer Research
- Mary Lanning Healthcare, Morrison Cancer Center, Hastings
- Faith Regional Health Services, Carson Cancer Center, Norfolk
- Great Plains Regional Medical Center, North Platte
- 他3件
被験者募集中観察研究健康なボランティア歓迎
19歳〜110歳 · 全性別 · 2026/06/29更新 · NCT02012699DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- USA14-0, Lincoln
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/22更新 · NCT06953089SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Omaha
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。